Sandra Kanan

2.3k total citations
23 papers, 765 citations indexed

About

Sandra Kanan is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Sandra Kanan has authored 23 papers receiving a total of 765 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 11 papers in Pathology and Forensic Medicine and 8 papers in Oncology. Recurrent topics in Sandra Kanan's work include Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (11 papers) and CAR-T cell therapy research (6 papers). Sandra Kanan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (11 papers) and CAR-T cell therapy research (6 papers). Sandra Kanan collaborates with scholars based in United States, Netherlands and United Kingdom. Sandra Kanan's co-authors include Steven P. Treon, Zachary R. Hunter, Jorge J. Castillo, Guang Yang, Yang Cao, Lian Xu, Kirsten Meid, Christopher J. Patterson, Adam J. Olszewski and Nickolas Tsakmaklis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Cancer.

In The Last Decade

Sandra Kanan

22 papers receiving 751 citations

Peers

Countries citing papers authored by Sandra Kanan

Since Specialization

Citations

This map shows the geographic impact of Sandra Kanan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Kanan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Kanan more than expected).

Fields of papers citing papers by Sandra Kanan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Kanan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Kanan. The network helps show where Sandra Kanan may publish in the future.

Co-authorship network of co-authors of Sandra Kanan

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Kanan. A scholar is included among the top collaborators of Sandra Kanan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Kanan. Sandra Kanan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Solomon A. Graf, Ryan D. Cassaday, Karolyn Morris, Jenna Voutsinas, Qian Wu, Fatemeh Behnia, Ryan C. Lynch, Elizabeth F. Krakow, Heather Rasmussen, Thomas R. Chauncey, Sandra Kanan, Lorinda Soma, Stephen D. Smith, Ajay K. Gopal	10
2	Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma 2018 ·Blood ·Stephen D. Smith, Ryan C. Lynch, Brian G. Till, Andrew J. Cowan, Qian Wu, Jenna Voutsinas, Mazyar Shadman, (unknown), Andrei R. Shustov, Sandra Kanan, (unknown), Ryan D. Cassaday, Jonathan R. Fromm, Ajay K. Gopal	2
3	Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma 2018 ·Blood ·Solomon A. Graf, Ryan C. Lynch, David G. Coffey, Mazyar Shadman, Sandra Kanan, Edward N. Libby, Edus H. Warren, Colin D. Godwin, Ted Gooley, Jonathan R. Fromm, Ajay K. Gopal	2
4	Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study 2018 ·Blood ·Solomon A. Graf, Ryan D. Cassaday, Karolyn Morris, (unknown), Pamela S. Becker, Thomas R. Chauncey, Sandra Kanan, Lorinda Soma, Stephen D. Smith, Ajay K. Gopal	1
5	Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy 2018 ·Blood ·Victor A. Chow, Ajay K. Gopal, David G. Maloney, Cameron J. Turtle, Stephen D. Smith, Mazyar Shadman, Ryan D. Cassaday, Brian G. Till, Yolanda D. Tseng, Edus H. Warren, Andrei R. Shustov, Manoj Menon, Sandra Kanan, Utkarsh Acharya, Erin Mullane, Lindsay M. Hannan, Jenna Voutsinas, Ted Gooley, Ryan C. Lynch	13
6	Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial 2017 ·Blood ·Ryan D. Cassaday, Jonathan R. Fromm, Andrew J. Cowan, Stephen D. Smith, Edward N. Libby, Mary Philip, (unknown), (unknown), Sandra Kanan, Fatemeh Behnia, Ajay K. Gopal	9
7	Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy 2017 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Sandra Kanan, Andrew J. Cowan, Edus H. Warren, Brian G. Till, Mazyar Shadman, Ryan D. Cassaday, Oliver W. Press, Andrei R. Shustov, Ajay K. Gopal, Stephen D. Smith	1
8	Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenstrom's Macroglobulinemia and IgM MGUS 2015 ·Blood ·Josephine M. I. Vos, (unknown), Kirsten Meid, Joshua Gustine, Christopher J. Patterson, (unknown), Sandra Kanan, Marie José Kersten, Steven P. Treon, Jorge J. Castillo	1
9	Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER database 2015 ·American Journal of Hematology ·Jorge J. Castillo, Adam J. Olszewski, Sandra Kanan, Kirsten Meid, Zachary R. Hunter, Steven P. Treon	16
10	Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database 2015 ·Cancer ·Jorge J. Castillo, Adam J. Olszewski, Zachary R. Hunter, Sandra Kanan, Kirsten Meid, Steven P. Treon	25
11	Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance 2014 ·Leukemia ·Lian Xu, Zachary R. Hunter, Guang Yang, Yang Cao, Xingguang Liu, Robert Manning, Christina Tripsas, (unknown), Christopher J. Patterson, Michael Kluk, Sandra Kanan, Jorge J. Castillo, Neal I. Lindeman, Steven P. Treon	64
12	The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia 2014 ·Leukemia ·Yang Cao, Zachary R. Hunter, Xingguang Liu, Lian Xu, Guang Yang, (unknown), Christopher J. Patterson, Nickolas Tsakmaklis, Sandra Kanan, Scott J. Rodig, Jorge J. Castillo, Steven P. Treon	154
13	CXCR4 WHIM‐like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88^L265P‐directed survival signalling in Waldenström macroglobulinaemia cells 2014 ·British Journal of Haematology ·Yang Cao, Zachary R. Hunter, Xia Liu, Lian Xu, Guang Yang, Jie Chen, Nickolas Tsakmaklis, Sandra Kanan, Jorge J. Castillo, Steven P. Treon	72
14	Clinical Characteristics of Rituximab Intolerance in Patients with Waldenstrom's Macroglobulinemia 2014 ·Blood ·Sandra Kanan, Kirsten Meid, Steven P. Treon, Jorge J. Castillo	3
15	Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of theSurveillance,Epidemiology andEndResults database 2014 ·British Journal of Haematology ·Jorge J. Castillo, Adam J. Olszewski, Sandra Kanan, Kirsten Meid, Zachary R. Hunter, Steven P. Treon	85
16	Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia 2014 ·Blood ·Steven P. Treon, Christina Tripsas, Kirsten Meid, Sandra Kanan, Patricia Sheehy, Stacey Chuma, Lian Xu, Yang Cao, Guang Yang, Xia Liu, Christopher J. Patterson, Diane Warren, Zachary R. Hunter, Barry Turnbull, Irene M. Ghobrial, Jorge J. Castillo	126
17	Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia 2013 ·Blood ·Steven P. Treon, Christina Tripsas, Kirsten Meid, (unknown), (unknown), Diane Warren, Claudia E. Paba‐Prada, Christopher J. Patterson, Guang Yang, Zachary R. Hunter, Janet Kunsman, Sandra Kanan, Irene M. Ghobrial	9
18	Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance 2013 ·Blood ·Lian Xu, Zachary R. Hunter, Guang Yang, Yangsheng Zhou, Xia Liu, Yang Cao, (unknown), Christopher J. Patterson, Christina Tripsas, Sandra Kanan, Jiaji G. Chen, (unknown), Steven P. Treon	2
19	Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker 2006 ·Cancer Epidemiology Biomarkers & Prevention ·Ingegerd Hellström, (unknown), Sandra Kanan, Niranjan Y. Sardesai, Thorsten Verch, Yi Yang, Karl Erik Hellström	96
20	Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137 2004 ·Proceedings of the National Academy of Sciences ·(unknown), Yi Yang, (unknown), Hongtao Zhang, Sandra Kanan, Yajun Guo, Ze’ev A. Ronai, Ingegerd Hellström, Karl Erik Hellström	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact